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ABSTRACT
Inhalable medications for patients with asthma
and chronic obstructive pulmonary disease
(COPD) can be confusing even for health care
professionals because of the multitude of avail-
able devices each with different operating
principles. Dry powder inhalers (DPI) are a
valuable option for almost all of the patients
with asthma or COPD. Based on recorded
patient inspiratory profiles, the peak inspiratory
flow requirement of 30 L min-1 of high-resis-
tance devices does not usually pose any practi-
cal limitations for the patients. Suboptimal
adherence and errors in device handling are
common and require continuous checking and
patient education in order to avoid these pitfalls
of all inhalation therapy. The aim of this opin-
ion paper is to describe the working principles
of DPIs and to summarise their key properties in
order to help prescribing the correct inhaler for
each patient.
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DIFFERENT TYPES OF INHALERS
The history of inhaler technology goes back
almost 250 years. The first time the word inha-
ler was used was related to the ‘Mudge’ Inhaler
in 1778 [1]. In modern inhalation therapy,
there are four main device types. The first
devices resembling nebulisers were introduced
in the 1860s, metered dose inhalers (MDI) were
developed in the 1950s, dry powder inhalers
(DPI) in the 1980s and soft mist inhalers (SMI)
after the year 2000.
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In 2006, Chrystyn et al. [2] proposed five
qualities which are required for an ‘ideal inha-
ler’. Firstly, the emitted dose must have appro-
priate aerodynamic characteristics to be as
much as possible independent of a patient’s
characteristics and clinical condition. Secondly,
delivery of the drug must be safe and effective,
thus maximising the therapeutic effects locally,
while minimising systemic effects. Thirdly, the
inhaler must be easy and intuitive to use.
Fourthly, the device must be appealing to the
patient to promote adherence and proper use.
And lastly, ideally, a single device type should
include all of the patient’s required inhalable
treatments.
Since 2006, there has been an increased
recognition of global environmental threats.
There has therefore been increasing pressure to
include environmental factors in the ideal fea-
tures. To limit the depletion of the ozone layer,
the permitted level of chlorofluorocarbons
(CFC) produced was reduced from 150% of
calculated levels of production and consump-
tion to zero between 1986 and 2010 by the
Montreal Protocol [3]. In response to these
changes, the pharmaceutical industry increased
its focus on the development of dry powder
inhalers [4]. While pressurised MDIs (pMDIs)
remain the most commonly prescribed type of
inhaler [5], even in the post-CFC era, they still
pose an environmental hazard [6], as the mod-
ern propellants (hydrofluorocarbons and
hydrofluoroalkanes) are roughly 1300 times
more potent than CO2 as greenhouse gases. In
fact, the carbon footprint of pMDIs has been
reported to be over 100-fold greater than that of
DPIs [7].
The properties of each device type, including
pros and cons, are outlined in Table 1: pMDIs
facilitate patient-independent aerosolisation,
but require sufficient coordination upon actua-
tion; nebulisers allow delivery during normal
breathing patterns, but are cumbersome to carry
and need cleaning and servicing; SMIs are por-
table, but like pMDIs handling and co-ordina-
tion for dosing may be difficult for some
subjects in comparison with DPIs; finally, DPIs
are convenient and lightweight but rely upon
patient inhalation technique to aerosolise the
drug powder [8]. Taking environmental
considerations into account, DPIs, being
portable and easy to use, offer an appealing
option for pulmonary drug delivery. Choosing
the right device for the right patient is not as
straightforward as it might first appear. Myths
and misconceptions persist—particularly with
DPIs—and debunking these will help clinicians
pick the best device for their patient. For these
reasons, this opinion paper aims to discuss the
benefits and drawbacks of DPIs, from both a
device and a patient’s perspective.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
FROM POWDER TO AEROSOL
Despite their apparent simplicity, dry powder
inhalers are sophisticated devices. In order to
deliver active drug to the respiratory tract, the
user must inhale through the device. This
inhalation provides energy which breaks up the
compacted drug powder, a process called de-
agglomeration, and transports this de-agglom-
erated drug into the lung [9]. Most DPIs contain
a micronised drug blended with carrier particles
such as lactose that prevent aggregation and
provide sufficient flowability. To enhance the
aerosolisation of the drug particles, fine lactose
particles are often added to the carrier lactose to
saturate high-energy binding sites on the carrier
lactose and form easily detachable aggregates
with the drug particles. Both mechanisms con-
tribute to higher fine particle dose, which is
defined as the dose able to penetrate deep into
the lungs [10–13].
When the patient activates the DPI and
inhales, airflow through the device creates shear
forces and airflow turbulence. As the powder is
emitted from the inhaler, the drug particles
separate from the carrier particles and are car-
ried deep into the lungs, while the larger carrier
particles end up in the oropharynx and are
swallowed/cleared [8]. Thus, the level of depo-
sition into the lungs is determined by a com-
bination of two factors: the patient’s inspiratory
effort and the device’s properties (e.g. shape of
the mouth piece, flow resistance and flow) [14]
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[15]. To achieve efficient aerosol dispersion,
drug formulations have been developed in
conjunction with varying DPI design elements,
such as swirl chambers, grids and lacunas, to
subsequently present varying degrees of airflow
resistance. Hence, each DPI results in different
pressure-drop and flow-rate characteristics. In
general, the flow rate though a DPI is propor-
tional to the square root of the pressure drop
that the patient develops across it. The constant
of proportionality is termed the device resis-
tance [16].
Counterintuitively, higher resistance is often
an advantage with DPIs. With the exception of
the Turbuhaler (AstraZeneca), medium-to-high-
resistance inhalers require lower patient inspi-
ratory flow rates for optimal performance
(Fig. 1) [17–22]. Generally, higher-resistance
devices generate more turbulent flow, more
effectively converting the work done by the
patient to energy available for de-agglomeration
of the drug particles [23–25]. In contrast, the
Turbuhaler uses a built-in cyclone to de-ag-
glomerate the formulation, and therefore has a
minimum threshold for inspiratory flow rate to
effectively aerosolise the drug particles [26]. In
breath-actuated DPI devices, a certain pre-de-
termined threshold in inspiratory flow rate has
to be achieved before the drug is released from
the inhaler. This prevents drug release at low
flow rates that would not be high enough to
allow effective de-agglomeration and would
therefore result in low pulmonary deposition.
Devices at the lower end of the resistance
spectrum use less manipulation of flow patterns
through the inhaler, and therefore rely more on
the patient generating a flow rate that achieves
sufficient de-agglomeration. With these princi-
ples in mind, patients with impaired pulmonary
function could benefit from devices with higher
resistance [21].
European and US pharmacopoeia recom-
mend the use of a standardised pressure drop of
4 kPa for in vitro characterisation of DPI prod-
ucts. As this was originally intended as a
method in quality control in the context of
batch release, it is ill suited to produce data
relevant to performance with patients. Recent
publications are instead reporting the use of
fixed ranges of inspiratory flow rates or patient
population-specific percentiles when trying to
simulate real-life conditions [18, 20, 27]. Haidl
et al. [28] have suggested criteria for a successful
inhalation manoeuvre, namely sufficient
device-specific inhalation flow rate, flow accel-
eration, inhalation volume and inhaled volume
after actuation. Based on this review, the peak
inspiratory flow rate (PIF) of 30 L min-1 is suf-
ficient for various DPIs of different operating
principles, e.g. Easyhaler (reservoir; Orion),
Fig. 1 Dry powder inhaler resistance and optimal peak inspiratory flow for adequate drug delivery
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Handihaler (capsule; Boehringer–Ingelheim)
and Ellipta (blister; GlaxoSmithKline). Patients’
inspiratory efforts have been shown to vary
between age ranges (from paediatric to geriatric)
and indications (from asthma to COPD)
[22, 29, 30]. However, the expected PIF of 30
L min-1 seems to be well within reasonable
limits. For example, when PIF was studied on
the Easyhaler (a relatively high-resistance device
compared with the Symbicort Turbuhaler) in
adult and paediatric patients with asthma, as
well as adults with COPD, the 10th, 50th and
90th percentiles for PIF were 44.7 L min-1, 61.1
L min-1 and 74.8 L min-1 [18], respectively.
Further, the dosing has been shown to be con-
sistent for PIF values of 28.3–74.8 L min-1
[31, 32]. (Fig. 2).
INHALER USE IN PRACTICE:
PITFALLS AND SUCCESSES
Drugs are only effective if they can reach their
site of action. In pulmonary delivery, the inha-
ler adds an extra step and a further potential
barrier. Clinicians working with patients will be
only too aware that there are many possible
ways to use an inhaler device incorrectly. Edu-
cation is vital and continuous re-education is
also required. Recently, this has been addressed
by third parties (e.g. https://www.rightbreathe.
com), who provide commercially independent
training materials and educational videos on
the use of inhalers, but more work is still nee-
ded. Melani et al. studied the user-associated
mistakes made by 1664 adults with asthma and
COPD who used MDIs and DPIs at home. The
most common mistakes made with DPIs were
exhaling into the inhaler before or after actua-
tion and a lack of holding breath after the
inhalation [33]. Sandler et al. showed that rel-
atively few inhaler-naı¨ve adults were able to use
an inhaler [either the Spiromax (Teva), Easy-
haler or Turbuhaler] correctly without training
(just over a third), but following careful guid-
ance by a healthcare provider (HCP),[95% can
master the technical aspects required for suc-
cessful inhalation [34]. Patient education is
required at diagnosis, at regular intervals, and
certainly if the inhaler device is changed. Con-
tinuous checking and coaching also promotes
the HCP–patient partnership and the active
involvement of the patient and reduces
unscheduled health care utilisation in asthma
Fig. 2 Comparison of two budesonide/formoterol DPIs 160/4.5 lg/dose, Easyhaler (a) and Turbuhaler (b) regarding the
consistency of the delivered dose at different inhalation flow rates [31]
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and COPD [35, 36]. Mistakes in the use of the
inhaler have been shown to affect outcomes,
but no conclusive evidence has been demon-
strated using direct comparisons between
inhaler types or devices [37–40]. Taking into
account that inhaler use has not improved
during the last 40 years, substantial effort is
needed from both HCPs and inhaler designers
to rectify this issue [41].
The range of different medications available
for administration via inhalers is vast and may be
a source of confusion, for HCPs and especially for
lay people. Patients with asthma are often satis-
fied with their reliever, short-acting beta agonist
(SABA)-only treatment, because of their quick
onset of action and immediate relief of symp-
toms. This may lead patients to believe that their
asthma is controlled by their reliever therapy;
however regular SABA-use is associated with
poor outcomes [42, 43]. Dispensing three or
more canisters of SABA a year is associated with
increased hospital attendance [44], and more
than 12 a year with risk of asthma deaths, [45]
even in patients with minimal symptoms
[46, 47]. This highlights the need to educate
patients regarding the functions of the different
drugs that they are prescribed. In the most recent
2019 Global Initiative for Asthma (GINA) report,
a trend to simplify the treatment regimen can be
seen [48]. The formerly used step 1 (SABA-only)
treatment regimen was disregarded. Instead,
with safety as the main priority, GINA now rec-
ommends that all patients with asthma should
be prescribed inhaled steroids intermittently (in
mild asthma) or continuously. GINA no longer
recommends SABA as first-line treatment and
recommends a combination of low-dose inhaled
corticosteroids (ICS) and formoterol as needed in
mild cases (less than 2 episodes of symptoms a
month) and as an alternative to regular ICS in
Step 2 of the GINA’s stepwise asthma manage-
ment approach. This treatment strategy has been
shown to reduce serious exacerbations when
compared with SABA-only and to be non-inferior
when compared with daily ICS and SABA as
needed [49, 50]. Furthermore, a real-world com-
parison of as-needed ICS-formoterol in GINA’s
stepwise asthma management approach, Step 1
and 2 patients with as-needed albuterol (salbu-
tamol) demonstrated significantly lower asthma
exacerbations in the as-needed ICS-formoterol
group [51]. As steps 1 and 2, according to the new
GINA strategy, can now be managed with single
combined treatment as needed it will simplify the
treatment. It also makes use of the incorrect
practices by patients with infrequent symptoms
not using their regular medication [52] and their
urge for reliever therapy to control their disease.
Therefore, the new GINA report takes a step
towards a Maintenance and Reliever Therapy
(MART) regimen, in which control and reliever
therapy is combined in a single product. The
concept of simplifying the treatment regimen has
previously been employed in other fields of med-
icine. For example, when treating hypertension
and dyslipidemia, medication may be combined
to a single tablet to increase patient adherence
[53]. It is worth mentioning that the studies cited
in the new GINA report were conducted only with
budesonide-formoterol combination therapy,
and the clinical data have been extrapolated to
also include other ICS. The recommendations are
currently off-label and specifically include low-
dose ICS-formoterol preparations to take advan-
tage of the rapid action of formoterol.
In a cost–benefit analysis by Haahtela et al.,
Finnish asthma-related healthcare costs
decreased by 14% between 1987 and 2013
despite a 3-fold increase in the number of
diagnoses and an increase in medication costs
[54]. As with the latest GINA guidelines, one of
the cornerstones of the Finnish asthma program
was to start inhaled corticosteroids as first-line
treatment for all patients. The results from the
program suggest that increased disease control
not only improves patients’ quality of life but
also provides wider societal benefits (e.g. eco-
nomic benefits and improvements in integrated
care) [55].
When compared with other types of inha-
lers, DPIs have a markedly different risk profile
concerning the ambient environment. While
they resist microbiological contamination
extremely well, they are often susceptible to
changes in their physical composition. For
example, changes in crystallinity or agglomer-
ation due to moisture may result in decreased
performance of the product [56]. When apply-
ing for marketing approval, all inhalers must
have evidence that they work well if stored
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according to their summary of product charac-
teristics. Therefore, patient training should not
be constrained to the use of an inhaler, but
should also include handling and storing of the
device.
INHALERS ARE FOR PATIENTS
From the patient’s perspective, the require-
ments for an ideal inhaler can be summarised
with six E’s (Fig. 3). An inhaler must be Effec-
tive; i.e. able to deliver the aerosols with par-
ticle sizes of respirable range and independent,
as much as possible, of the inhalation volume
and flow rate. This minimises the variation
between patients, but also guarantees effective
treatment when a single patient’s clinical
parameters vary during treatment. Successful
delivery straight to the site of action also
allows the drug to act with minimal adverse
effects. An inhaler must also be Efficient, i.e.
easy to handle and able to be used with rela-
tively few handling steps; these properties
contribute to compliance and error-free han-
dling. An Engaging design promotes patient
satisfaction and adherence, leading to better
treatment outcomes. Despite all the training
and efforts of the HCPs, patients will continue
to make errors with their inhalers; therefore, a
well-designed inhaler is Error-tolerant and will
minimise the effects of at least the most com-
mon user errors. An inhaler should also be
Easy-to-teach; when teaching the use of an
inhaler is easy and fast, the HCP can check the
patient’s inhaler technique more easily and
retrain the patient in using their device.
Improvements in patients’ technical profi-
ciency are likely to result in better treatment
outcomes as the doses are more consistently
delivered to the site of action. Chronic diseases
as asthma and COPD are not only problematic
for patients themselves, but provide a consid-
erable societal burden; therefore, an ideal
inhaler is also Easy-to-switch to when needed
(e.g. at the population level, for cost-effective-
ness reasons).
Patients of all ages have been reported to be
particularly poorly adherent to inhaled medi-
cation [57, 58]. To address this problem, many
companies have developed web-based informa-
tion platforms (e.g. https://www.wehale.life/
[Orion pharma] and https://www.asthma.com/
;Glaxo-Smith Kline) and inhaler-mounted smart
devices, to give advice and feedback to the
patient. Current guidelines on asthma and
COPD promote the active involvement of the
patient when choosing the inhaler. Satisfaction
with an inhaler has been shown to relate to
adherence and asthma control [59]. Differences
in satisfaction between inhalers have been
reported to arise from convenience-related fac-
tors such as portability, weight and size, and
from usability factors such as preparation and
use [60]. Several studies have reported thera-
peutic equivalence and successful switches
between the inhalers (e.g. from Turbuhaler to
Aerolizer, Spiromax, Easyhaler and Novolizer)
[61–64]. An example of a large scale switch in
real-life practice comes from Norway, where the
health authority (Statens legemiddelverk)
included the Bufomix Easyhaler and Duoresp
Spiromax in its switch regimen of DPIs con-
taining budesonide/formoterol in Norwegian
pharmacies, starting on July 1, 2018 [65].
CONCLUSIONS
In the market, there are many devices which are
capable of delivering the drugs to the lungs of
the patient. The myriad of devices and complex
physics involved in the delivery makes it diffi-
cult for clinicians to choose the right device for
their patients. For the majority of patients,Fig. 3 Six E’s
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there is a sufficiently effective combination of
drug molecules available for use. However, poor
adherence and incompetence with the device
remain as frequent problems in inhalation
therapy. Most patients are able to use nebulisers
and pMDIs as well as high- and low-resistance
DPIs. There is rarely a single best device for any
given patient, and the choice should be made
with the patient to take into account the
parameters which are important to the actual
user, such as size, portability or environmental
factors. These properties valued by the patients
may be medically irrelevant but through
adherence could be the defining factor in the
success of the treatment.
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